Part IThe Story
It was raining on Killian Court on May 30, 2024, and the man who had been asked to give the commencement address at the Massachusetts Institute of Technology was standing up to give it when the ceremony came apart around him. Mark Gorenberg, chair of the MIT Corporation, had finished his introduction. Noubar Afeyan, sixty-one, a big man in academic robes, founder and chief executive of Flagship Pioneering, co-founder and chairman of Moderna, rose from his chair. And dozens of graduates rose with him. Banners unfurled at the front of the seating, protesting the suspension of student demonstrators and calling for divestment. Over a hundred students stood and chanted. Israeli flags appeared in the crowd. Boos came down from parts of the audience. The livestream cut to a placard that read, simply, "Interlude," and light music played over the feed while protesters walked the perimeter of the seated graduates.
Afeyan sat back down.
That is the detail worth holding. He did not try to talk over it, did not leave, did not appear to argue with it. He returned to his seat and waited, which is a thing people who have spent their lives in other people's emergencies learn how to do. When he finally took the podium, he began with a courtesy so dry it could pass for a joke — "Thank you, Mark, for that generous but somewhat embarrassing introduction" — and then, within a minute, he was in Beirut. A ninth-floor apartment. Three generations of an Armenian family under one roof. A bedroom shared with a great-aunt, its window looking "out over the red-tiled roofs of Roman, Ottoman, and Byzantine buildings and beyond to the Mediterranean Sea." Then the civil war of 1975, the curfews, and a strange side effect of the curfews: the state broadcaster, which ordinarily aired three hours of programming a day, went round-the-clock, filling the hours with American television for a population ordered indoors. He and his brothers watched. One show in particular set his heart racing.
At that point in the speech, on a wet afternoon in Cambridge, with protest banners still somewhere in his peripheral vision, the MIT sound system played the theme from Mission: Impossible.
"Your mission, should you choose to accept it …" He quoted the encoded, self-destructing message that opened every episode, and then made the claim on which the next forty minutes — and, arguably, the previous forty years — rested: "In the fifty years since, I have been consistently drawn to impossible missions."
It is a good line, and it is also a little bit of a put-on, the kind of thing a man says when he knows exactly what a commencement crowd needs. But it contains an odd and very precise truth. The boy who fell for Mission: Impossible was not watching it in freedom. He was watching it under curfew, in a city coming apart, inside an apartment holding a family that had already been forced out of two countries in two generations — a family whose stories of survival, told to him across a shared bedroom by a woman seventy years his senior, were themselves stories of impossible missions accepted because the alternative was death. The television show was an American fantasy of competence under pressure. The bedroom was the real thing.
Everything that came after — the first company launched days after the worst stock crash in modern memory, the decade running a public instruments company, the invention of a firm that numbers its companies at birth so that it can kill them, the eighteenth such number becoming Moderna, the billion doses, the backlash, the Armenian philanthropy, the letters to the New York Times — orbits that apartment. Afeyan has spent four decades building an institution whose purpose is to manufacture breakthroughs on schedule. He has done it, by his own repeated account, with the instincts of someone who learned early that the world can be ended and restarted from zero, and that the skill that matters most is knowing what to carry out.
By the Numbers
The Afeyan Ledger
118Companies Flagship had launched over 25 years, as of November 2025
$100B+Aggregate value of ventures developed by Flagship, per the firm
~$52BAggregate exit value from Flagship ventures (May 2026)
$604MModerna's December 2018 IPO, then the largest in biotech history
1B+Moderna COVID-19 vaccine doses produced per year at the 2022 peak
~700Patents Flagship files per year
100+Patents bearing Afeyan's name as inventor
A Bedroom With Two Calendars
From the time he was a baby until he was twenty, Noubar Afeyan shared a bedroom with his great-aunt Armenouhi. They were roommates in Beirut, and then — when the family left — roommates again in Canada. She lived until she was almost 101. He has said her memory and spirit still live in his house, "not just in my mind," which is the kind of phrase that sounds sentimental until you consider the arithmetic: a man whose bedroom companion for two decades had been born into the Ottoman Empire and come of age during a genocide. He was sleeping, effectively, in two centuries at once.
Armenouhi had a theory of victory. "I remember her saying that the best way to win is to create, to excel, to do great things," Afeyan told the Aurora Humanitarian Initiative. "By 'win' she meant beat the Genocide."
It is worth sitting with that formulation, because it does not mean what an American self-help sensibility would want it to mean. She was not telling the boy to follow his dreams. She was describing creation as a form of counterattack — the production of excellence as the only available response to people who had tried to erase you, and who, in the decades she was describing, had never been made to admit it. Afeyan has called it "this overhang of an unrecognized genocide," and he has written about the specific, peculiar way that overhang shaped a childhood. "One of my most searing memories of my childhood in Beirut relates to events that had taken place more than 50 years before," he wrote on April 24, 2024 — the day Armenians mark the beginning of the 1915 deportations.
— Noubar Afeyan, April 24, 2024I can't fully describe what it is like to be a child who learns, before learning math or the alphabet, that you are part of a community others sought to extinguish.
Armenouhi's own family had survived, in her telling, by a combination of luck and usefulness. Her husband, Antranig, was a physician skilled enough to be employed by the Ottoman army. "Ottoman soldiers who massacred Armenians protected him because he protected them," Afeyan recalls — a sentence with an entire moral universe compressed inside it, in which competence is not a virtue but a survival credential, a thing that makes you worth keeping alive to the people who are killing your neighbors. Her two brothers, Bedros and Nerses, had a stranger story still, which the family carried through Bulgaria and Lebanon and Canada and which this piece will return to.
Afeyan's father, Badrig, was born in Bulgaria in 1929. The Afeyans had run a business exporting eggs from Turkey to Bulgaria, and some of the family had moved north after 1918 — which meant that when communism arrived, they had to move again, this time to Beirut. There, Badrig built a business importing and exporting plastics across the Middle East. Noubar's mother had studied piano at the Paris Conservatory and taught lessons in the city. Three sons. Three generations. A ninth floor. One version of the family biography, published in Forbes in 2016, describes Noubar as "the grandson of an Armenian refugee who landed in Lebanon after he was saved during the genocide by German officers" — a compression that slightly scrambles the version Afeyan tells at greater length, in which the Germans saved a great-aunt's brothers rather than a grandfather. Diaspora stories do this. They get retold in airports and at dinners and on podcasts until the branches of the family tree grow together, and what survives is the shape: the train, the Germans, the escape, the starting over.
Starting over is the shape. Afeyan's paternal line had done it in Anatolia, then in Bulgaria. His mother, by one account Lebanese-born, could not pass Lebanese citizenship to her children because Lebanese law still bars mothers married to foreigners from doing so — which means that the boy who would one day receive Lebanon's National Order of Merit, presented in 2021 by Ambassador Gabriel Issa on behalf of President Michel Aoun alongside seven other Lebanese at Moderna, grew up in a country that had never formally made him its own. He learned English, he has written, "as a second language after Armenian (and before Arabic and French)." The order of that list is a map.
Less Than a Week
The family left in 1975, early in the war, and the reason they left was not the bombing. "We left Lebanon fairly early at the start of the Civil War, because my dad thought it would severely impact the education of his three teenage sons," Afeyan said in 2024. "He made a big sacrifice in leaving the relative ease of earning a living he had in Lebanon. We ended up going to Montreal, where he started all over again."
There is a version of immigrant mythology in which departure is a single heroic act, and there is the version Afeyan tends to tell, which is more like a closing window. "We barely made it out," he wrote in 2022. "Less than a week after our departure, the Beirut airport closed to commercial air traffic for five years." Six days, maybe five, between a family that got out and a family that would have been stuck for half a decade inside one of the twentieth century's most grinding urban wars. The difference between those two outcomes was a father's judgment about schooling and a narrow interval on an airline schedule. It is not the sort of thing a person forgets. It is the sort of thing a person might spend a career trying to engineer out of existence — the dependence of everything on a margin you cannot see.
Canada took them. Afeyan has been consistent and almost formal in his gratitude about this. Canada, he told Harvard Business School's Gary Pisano in December 2019, "graciously accepted my family as escapees from the civil war, giving us citizenship." It was, he wrote later, "a country whose immigration policies allowed for refugees to arrive and resettle. It's fair to say those enlightened and humane laws created the opportunities that have shaped my professional life."
What did he bring? He has given the inventory himself, and it is a good inventory because it is mostly absence: a thirteen-year-old "speaking imperfect French, having never experienced snow, ridden a city bus, or set foot in a biology or chemistry lab." Montreal in 1975 was a city in the middle of its own language war, and the boy from Beirut had the wrong French and no winter coat in his vocabulary. He went to Loyola High School, a Jesuit school in the city's west end, graduating in 1978. And Armenouhi, still, in the next bed.
He chose engineering partly out of affinity for physics and mathematics and partly, as he later told the American Institute of Chemical Engineers, because of what his father did for a living. Badrig had been in plastics in Beirut and went back into plastics in Montreal. The son went into chemical engineering at McGill, spending summers at Union Carbide and Dow Chemical — two names that now read like an archaeological layer of North American industry — and graduated with a bachelor's degree in 1983. It is easy to miss how much continuity sits inside that decision. The refugee story is supposed to be about rupture. This one keeps folding back on itself: eggs to plastics, plastics to polymers, polymers to the molecules of life. The father restarts a business; the son studies the chemistry of the thing the father sells.
Then Boston. MIT was recruiting its first cohort of doctoral students in a field that barely had a name yet — biochemical engineering, the point where chemical engineering, computing, and the new molecular biology were beginning to collide. "I was drawn to the cutting-edge technology of the field," he said. "It was a big deal back in the day." His thesis adviser was Daniel Wang, later an Institute Professor and regarded as one of the founding fathers of the discipline. Afeyan would become the first PhD graduate of MIT's Center for Bioprocess Engineering, at the time the only institution offering that degree.
The first graduate of the only program. It is an immigrant's position rendered in academic form: the person who arrives somewhere before the institutions have hardened around it, and who therefore has no choice but to help build them.
The Man Who Sat Down at Lunch
In 1985, Daniel Wang could not attend a National Science Foundation conference in Washington, so he sent his graduate student as a proxy. At lunch, Afeyan sat down beside a stranger. He later described the man as "someone close to my father's age" — a telling choice of reference point for a twenty-three-year-old whose father was, at that moment, restarting a plastics business in Montreal.
The stranger asked about his research and then told a story about himself. Over forty years earlier, he and a colleague had been trained in a then-new discipline, electrical engineering, and hadn't known what to do with it. So they decided to make instruments — tools for testing circuits — and started a company in a garage with a group of friends. They talked for a while before Afeyan learned his companion's name: David Packard.
"A lightbulb went off for me that day," Afeyan wrote on National Entrepreneurs Day in 2023. "I too was becoming a new breed of engineer, as one of the first students in MIT's then-new program in biochemical engineering. Maybe I can create a company to make the instruments this field is going to need."
It is the most famous anecdote of his early career and also the most structurally revealing, because the lesson he took from Packard was not "be bold" or "start a company." It was an analogy, mapped with an engineer's precision: a new discipline produces practitioners before it produces their tools; whoever builds the tools for the new breed builds the industry's infrastructure. Afeyan had expected to go into the pharmaceutical industry. "But after learning how he and Hewlett had started Hewlett Packard," he said, "I decided that I would try to start a company." He went back to Cambridge and, by his account, learned everything he could about how that was done.
The timing was comically bad. He made his first investment pitch, he has said, on the Tuesday after Black Monday — October 19, 1987, the day the stock market collapsed. "There was this once-in-a-generation event where the stock market dropped by about 50 percent, and I was a 25-year-old recent Ph.D. graduate of MIT, and I had no idea why that should matter." In other tellings he is twenty-four. The age shifts by a year depending on the interview, which is both perfectly human and somehow fitting for a story about a young man who did not yet know which numbers mattered.
What mattered, it turned out, was not the index but the norm. "It was crazy because back then, if you were 24 years old and an immigrant, you didn't actually start companies," he told AIChE. On the No Priors podcast he elaborated: in that era, the people "entrusted with the massive amounts of venture capital, namely two, three million dollars per round," were former senior executives from Merck or IBM. The founder was supposed to be a well-established American man deep into middle age. Afeyan was none of those things. He raised the money anyway — "quite a bit of venture money," he says — and started down the road.
A year earlier, at an American Chemical Society meeting in Anaheim, California, a mutual acquaintance had introduced him to a Swedish biochemical engineer named Anna Gunnarson, visiting on business for the industrial firm Alfa Laval, to discuss one of his projects. Her family history has the same hinge in it as his, turned to a different angle. "My dad ended up being a lawyer — his dad was a blacksmith," she has said. "My mom ended up a high school teacher — her dad was a snowplow driver." Blacksmith to lawyer, snowplow to classroom: a Scandinavian version of the education-as-escape-velocity story, minus the genocide but plus the winters. Her parents used to invite newly arrived immigrants to Christmas dinner. She moved to the United States in 1988. They married, raised four children in Lexington, Massachusetts, and eventually built a philanthropy together that, she says, she approached with the culture shock of someone from a country where the state took care of basic needs and private giving was not a civic religion.
It is hard not to notice that the most consequential relationships of Afeyan's early adulthood were both formed at scientific conferences he attended somewhat by accident — once as a proxy, once as the subject of an introduction. A man who would later argue that breakthroughs can be systematized has two of the great non-systematic encounters in his own origin story. He seems aware of this. "Many forces and factors have conspired," he wrote, "often in surprising ways, sometimes without even knowing."
Ten Years of Postgraduate Education
The company that came out of the Packard lunch became PerSeptive Biosystems, and Afeyan ran it for a decade. It made instruments for the protein side of the life sciences — chromatography and the like, the analytical and separation machinery that biotechnology needed as it industrialized. PerSeptive went public in 1992. Annual revenues reached $100 million within six years of first sales. By the end it had some 880 employees, more than 200 of them with advanced degrees, and Afeyan describes it as having become "the largest instrumentation company on the protein side of the life sciences." In 1997 it agreed to merge with Perkin-Elmer, the DNA-instrumentation leader, in a stock swap valued at $360 million; the deal closed in 1998.
He calls those years "an intense 10-year, postgraduate education in everything related to applying science, engineering, innovation, IP, and marketing to business." The phrasing matters. Afeyan does not narrate PerSeptive as a triumph or as a founder's war story. He narrates it as a course of study — which is to say, as raw material for a theory.
The theory began forming inside the company. Sitting atop a building full of people with doctorates, he started noticing how many ideas were spilling off the main line of business, and he began spinning some of them out and partnering with others to start new companies — while still running PerSeptive. "I realized that becoming a co-founder is an interesting concept relative to a solo founder and that you could do more than one thing in parallel," he told Pisano. "The notion of parallel entrepreneurship made me ask: Can you do more this way than improvisational entrepreneurship?"
Within ten years of the first company he had founded or co-founded five more. Some of the names from that period — Chemgenics Pharmaceuticals, later acquired by Millennium; Color Kinetics, later acquired by Philips — sound now like footnotes, but they were the experimental runs of an idea. He was testing whether a person could hold several startups in mind at once without the whole thing collapsing into distraction. He was also, quietly, testing whether the romance of the founder was necessary at all.
After the merger he became senior vice president and chief business officer of Applera, the Perkin-Elmer parent, where he initiated and oversaw the creation of Celera Genomics — the company that would race the publicly funded Human Genome Project to sequence the human genome. It was a vantage point that few people in the industry ever occupy: an instruments maker turned corporate executive, standing inside the machinery that was about to turn biology into an information science, watching a company spun up deliberately from a parent's assets to chase a single enormous target. Celera is rarely mentioned at length in his interviews. But it is hard to read his later career without seeing it there in outline: a new company, conceived inside an institution, aimed at something nobody thought could be done on that timeline.
By the late 1990s, he had arrived at a question he says he'd been asking since the early part of the decade, a question he would go around posing at meetings like a man looking for an argument: "Why isn't entrepreneurship a profession?"
The Undertaker's Word
He has a riff about the word itself. He delivered a version of it to Forbes in 2016, sitting in an interview as, in the reporter's description, "a big, affable man" who "loves to teach."
"It's a complete misnomer," he said. "Do you know what the root of that word is? It's the French word for undertaker. It's the state of being something. I think it should be 'ing.' Entrepreneuring."
The French entrepreneur means, more neutrally, one who undertakes. But the macabre slippage into undertaker — the funeral director — is a joke that only works if you've lived in more than one language, and Afeyan has lived in four. It is also, read a certain way, not entirely a joke. By the time he was making it, he had built an institution whose defining feature is how efficiently it buries things.
The institution was founded in Cambridge in 1999 or 2000 — the firm's own literature says 2000; other accounts say 1999 — with Ed Kania, under the name NewcoGen, short for "new company generation." Several of the early partners had come from the venture firm Morgan Holland. The name was later changed to Flagship Ventures and then, in 2016, to Flagship Pioneering, a rebrand meant, according to the Boston Business Journal, to ensure the firm still "feels like a startup." The progression of names tells the story by itself: from a description of an output (new companies), to a category of finance (ventures), to a verb (pioneering). The word "entrepreneur" got its "-ing." So did the firm.
What Flagship actually is has always been hard to say, and Afeyan concedes it. "We are an institution that creates, repeatedly, breakthrough innovations or discontinuous advances," he told Semafor's Andrew Edgecliffe-Johnson in November 2025. The second thing it has systematized, he said, is converting those breakthroughs into companies — a process "historically viewed to be a highly idiosyncratic, low-likelihood event, and we don't believe that. We believe that there's a form of entrepreneurship that should be viewed as a professional act, not an amateur act." Entrepreneuring, he said, means "you're doing something, not being someone."
The mechanics are unusual. Flagship does not primarily wait for founders to walk in with pitch decks. Its in-house teams — originally organized as a unit called VentureLabs — begin with questions. As of a 2025 count, of roughly 110 companies Flagship had launched, almost 90 had been conceived entirely in house. The questions are deliberately extravagant. "I constantly say things that are unreasonable and seemingly crazy," Afeyan told Forbes in 2021, and then listed some: What if microorganisms living in the gut could help cure cancer? What if red blood cells could transport drugs along with oxygen? What if not all viruses were bad?
Promising questions become projects, and projects are given not names but numbers. "We number all of our companies at birth," Afeyan told Semafor. "We bless them with the indignity of having a number. That way, we can kill them. And the ones that don't die end up with a name."
It is the best sentence he has ever said in public, and it carries more weight than he lets on. Its mechanics are pure management psychology: a number has no ego, no brand, no team T-shirts, no sunk emotional cost; killing "LS18" is easier than killing a company someone has already fallen in love with. Each numbered project is bombarded, in its early days, with what Flagship calls "killer questions," and the survivors are, in his framing, the ones that withstood selection pressure. Afeyan has explicitly modeled the whole apparatus on evolution — he co-wrote a Harvard Business Review piece with Pisano titled "What Evolution Can Teach Us About Innovation," and he describes Flagship's methodology as laboratory-based evolution, in which "variation is created systematically and selection pressure is applied iteratively."
— Noubar Afeyan to Fortune's Alan Murray, May 2020When we start these things, they are completely unreasonable, and therefore dismissed… We have to start with science fiction and take the fiction out.
Flagship's surviving companies operate for a time as wholly owned subsidiaries; the strongest take outside capital and, ideally, go public. By late 2021, Forbes counted about seventy companies started under Afeyan at Flagship and thirty that had completed the entire process. By 2025, a new partner joining the firm could describe it, without much exaggeration, as having founded more than a hundred companies, thirty of which had gone public. The firm employs about six hundred people, more than half of them scientists, engineers, or physicians, and files on the order of seven hundred patents a year. It sits in offices overlooking the Charles River. "Everything we do," Afeyan likes to say, "is a bicycle ride away from here."
In 2013, writing for PharmaVoice, he had described the alternative he was trying to replace. The life sciences, he wrote, largely relied on "a marketplace, almost like a bazaar, where people — small companies — bring their wares … and then pharma companies go shopping." A Beirut boy reaching for the word bazaar to describe Big Pharma's business-development function is not choosing his metaphor by accident. He knows what a bazaar is, and he knows it is a wonderful place to buy spices and a terrible way to supply an industry. "Innovation is haphazard and accidental," he wrote. "There is a lot of money, time, and talented careers being wasted."
The word he uses most often for what Flagship does, though, is not systematic. It is unreasonable. "The things we work on are all unreasonable, and I mean that in the literal sense of the word, because only things that are proximal are reasonable," he told WBUR in 2018. "Keep in mind, we're using science that has not yet been discovered, in order to come up with treatments that have not yet been described, for diseases that are not well understood." That sentence would make any investment committee break out in hives. It is, in a sense, the firm's entire pitch.
LS18
The eighteenth number belonged to messenger RNA.
By 2010, experiments in two academic labs — at the University of Pennsylvania and at Harvard — had shown that mRNA with certain chemical modifications could be translated into protein inside cells more efficiently and with less of the adverse immune response that had sunk two decades of earlier attempts. Afeyan and his Flagship colleagues read those findings and started a project. "These findings led my colleagues and me to initiate a project we named LS18," he wrote for the National Academy of Engineering in 2021, "the 18th such scientific platform undertaken by Flagship Pioneering and the precursor to what became Moderna." Life Sciences 18. Three academic co-founders were involved. The founding question, as Afeyan later put it to an audience at MIT's Kuo Sharper Center, was absurdly broad: "What if you could use the human body to make any drug that you want?"
Not a drug. Any drug. That is the difference between betting on a product and betting on a platform, and it is the distinction Afeyan would hammer for the next decade. "All of our companies have decided that the way to innovate and create new products in this field is not by betting on a drug, but to bet on a platform that can generate many," he said in 2018. "Those companies require a lot more capital, but also provide a lot more opportunity for reward."
They also require someone to run them. In 2011, the person Afeyan wanted was Stéphane Bancel, a French chemical engineer then running BioMérieux, the French diagnostics maker — an executive from the measurement side of medicine, which is to say from the same instruments-and-tools world Afeyan had come out of with PerSeptive. Bancel did not want the job. "I said, 'You're crazy, it's never going to work,'" he recalled to Forbes. What changed his mind, he said, was not data.
— Stéphane Bancel, Moderna CEO, to Forbes (2021)Noubar's genius was not trying to force the issue in my brain, but to make me think that it could change the world and that it was worth the risk.
Bancel joined Flagship as a senior partner and then became the chief executive of LS18. The number got a name. And then for nearly a decade, Moderna did what platform companies do, which is spend extraordinary sums of money without selling anything. It built the chemical modifications, the delivery technologies, the design software, the automated systems to produce thousands of different mRNAs, the manufacturing processes for lipid nanoparticles. It accumulated a pipeline of twenty-four mRNA-based therapeutics and vaccines. By 2015 it was reportedly valued at $3.5 billion. By mid-2018, still private, it was the most valuable venture-backed startup in Massachusetts, at $7 billion — what WBUR's interviewer called "the ultimate unicorn in biotech." Afeyan took issue with the term. "This expression 'unicorn' is used in a derogatory way, because unicorn is what people call things that are not real," he said. "I would say that a 'unicorn' is a revolution that hasn't yet succeeded in technology."
In December 2018, Moderna went public in an offering that raised about $604 million, the largest biotech IPO in history at the time — for a company with no approved product, no late-stage results, and no near-term revenue. "Despite the progress and over $2 billion spent," Afeyan wrote later, "mRNA had still not yet been approved for use as a human medicine by early 2020."
In December 2019, Gary Pisano sat down with Afeyan at Flagship's offices for a long conversation about whether breakthrough innovation could be systematized. Read now, the transcript has the eerie quality of a photograph taken minutes before an earthquake. Neither man mentions a virus. They talk about parallel entrepreneurship, about PerSeptive, about the Flagship model. Within weeks, the platform that had consumed two billion dollars and ten years without producing a single approved medicine would be pointed at SARS-CoV-2.
The speed was the proof of concept. Beginning in late January 2020, at the urging of public-health officials, Moderna used its platform to design, fabricate, test, and scale up mRNA-1273. By late February it had shipped the first clinical batch to the National Institute of Allergy and Infectious Diseases for a Phase 1 study at Kaiser Permanente's research institute in Seattle, in forty-five healthy volunteers — the first SARS-CoV-2 vaccine to enter human trials. In March, Afeyan told the Armenian outlet CivilNet, with notable caution, that "the speed of entry to the clinic has been without precedent," and that "timing is hard to say." In May came early data: a small group of eight people, every one of whom developed antibodies. Afeyan was telling Fortune the company aimed for a billion doses a year of capacity by the end of 2021. The stock had already quadrupled since January.
On November 15, 2020, after four months of large-scale Phase 3 testing, Moderna learned that its vaccine worked — in the end-of-trial analysis, roughly 94 percent effective. A decade of platform-building had been compressed into a single, almost absurdly public demonstration. "There was no 'aha' moment when the mRNA breakthrough happened," Afeyan and Pisano wrote. The "aha" was in the construction, spread across years and hundreds of people. The world simply saw the last frame.
Canada, which had taken in a refugee family from Beirut forty-five years earlier, was among the first countries to pre-order. In 2021, Afeyan announced that Moderna would not enforce its patents against anyone making COVID-19 vaccines. By 2022, at its peak, the company was producing more than a billion COVID doses a year, and Afeyan says he was personally thanked by Qatari officials because Moderna's technology had allowed that year's World Cup to happen. A sentence like that is either the most surreal thing in this profile or the most ordinary; it depends on your tolerance for the way global history now passes through Kendall Square.
Asked by Boston magazine in 2025 how it felt to be one of the people who ended the pandemic, he declined most of the credit. "I've worked for the past 38 years, making innovations and creating companies that can have some kind of impact," he said, "and I could've worked another 38 years and not had that kind of impact. But the circumstances were such and the odds played out in a way that our science and our approach turned out to produce an effective vaccine."
The odds played out. The man who built an apparatus to drive luck out of innovation describes his single greatest outcome in terms of odds — a refugee's honesty about margins, five days between one airport and a five-year closure.
The Scary Part of Everything
The 2025 Boston magazine headline ran: "Moderna Cofounder Noubar Afeyan Is Afraid of Everything—And That's His Genius." It is a slightly overcooked framing of something Afeyan has been saying for years in calmer terms. "I can see the scary part of just about everything," he told Jonathan Soroff, "because we have to imagine it to try and go after it." On a Nature Biotechnology podcast in 2020 he had a phrase for it: immigrants and entrepreneurs both benefit, he argued, from being "paranoid optimists."
The paranoia is not abstract. He lost both his parents to cancer. "It continues to be a haunting feeling," he said, "that the very nature of cells, which is their evolutionary tendency to mutate, can be turned against the body they're in. Cancer is a pure disease of evolution." This is a man who designed his firm on the principles of variation and selection and who has watched the same principles, inside the bodies of his mother and father, produce the thing that killed them. Evolution is his method and his nemesis. He seems to hold both thoughts without strain.
And then, in the years after Moderna's triumph, the paranoia started looking like prophecy. In May 2023, he told the Financial Times that American politicians and judges needed to stop questioning established science and overruling regulators. By 2025, the company that had been perhaps the world's most celebrated had become, in STAT's description, "a target of government officials promoting falsehoods about mRNA technology." The Trump administration canceled a $766 million contract to prepare a vaccine against a potential bird-flu pandemic and replaced members of the federal vaccine advisory committee, partly with people who had expressed hostility to mRNA vaccines or to vaccines in general.
At the STAT Summit in Boston in October 2025, he sounded less like a chairman managing a stock price than like a man who recognized a pattern. The notion "that people can play with science, scientific fact, and essentially say opinions could be replaced for facts, or facts should be taken for opinions," he said, "isn't going to stop at mRNA, isn't going to stop with vaccines, childhood vaccines. It's going to go to every medicine." The scientific method's built-in skepticism, he argued, was being used as an opening for people to arrive "with zero background, zero hypothesis, and just make s— up." Already, he said, people were questioning chemotherapy. "If that happens, I don't know how you treat Alzheimer's or Parkinson's."
On the same stage, Arie Belldegrun — the Israeli-born urologist and serial founder who had built and sold Kite Pharma, one of the first CAR-T cancer companies, for $11.9 billion — offered the more diplomatic posture: he shared the worries but emphasized the positives, recounting a conversation with FDA Commissioner Marty Makary about streamlining trials. Belldegrun's career, like Afeyan's, is an immigrant's long bet on American scientific institutions. The difference that afternoon was temperament. Afeyan understood why his colleagues might reach for the hopeful version. "When you're in a storm, you kind of hang on to a tree," he said. He did not seem inclined to hang on.
In January 2026, on the first day of the J.P. Morgan Healthcare Conference in San Francisco — the industry's annual high mass — Flagship issued Afeyan's annual letter to investors. In it he recalled a former world leader describing lenacapavir, Gilead's twice-yearly injection to prevent HIV, as "a man-made miracle," and then warned that research cuts and political decisions were "taking a sledgehammer to our miracle machine." The letter warned that the backlash could endanger American life expectancy and hand China a scientific and economic edge.
The miracle machine. It is a strange phrase from a man whose life's argument has been that miracles are a misnomer — that what looks like a miracle is the output of a process. But it is the phrase of someone who knows that institutions, too, can be extinguished; that the systems that make breakthroughs routine are themselves contingent, built by immigrants and refugees in the margins that particular laws and particular moments allowed. The 2024 version of this anxiety, in his annual letter, had a name he admitted to borrowing: polycrisis, the term popularized by the historian Adam Tooze. Afeyan, who says he delights in new English words and sometimes invents his own "to the dismay of my family and colleagues," immediately invented the counterweight: "poly-opportunity." At Flagship, he wrote, "we intentionally throw ourselves off balance to stimulate the ingenuity and creativity needed to invent transformative technologies and companies."
Throwing yourself off balance on purpose is a peculiar discipline. It is the voluntary reenactment, in a corporate setting, of the involuntary thing that happened to him at thirteen.
Super-Survivors
"Armenians have one thing in common," Afeyan told the Aurora Humanitarian Initiative. "We're super-survivors. We're descendants of those who adapted and overcame seemingly impossible odds during the Genocide." In a 2020 interview with KTLA, he put the same idea in a more uncomfortable register: "One of the only unfortunate advantages Armenians have had by having gone through a genocide and having spread around the world is that we do have an experience of escaping and of immigrating and of constantly restarting."
Unfortunate advantages is a phrase that only someone deeply inside the experience could get away with. It is also the hidden engine of his second career, the one that runs in parallel with Flagship and draws on the same capital, the same convening instinct, and very often the same partners.
His urge toward philanthropy, he has said, emerged in the early 1990s, after he and Anna married, as newly independent Armenia struggled through the poverty that followed the Soviet collapse. The work matured through a partnership with Ruben Vardanyan, a Moscow-based Armenian investment banker who had built one of Russia's leading financial firms and then turned much of his energy and fortune toward the country of his ancestors. In 2001, Afeyan, Vardanyan, and others launched "Armenia 2020," an exercise in imagining the country's development prospects two decades out — a future-back exercise, in Flagship terms, aimed at a nation instead of a molecule. In 2005 they presented its key directions to President Robert Kocharyan. They founded the Initiatives for Development of Armenia, which, according to the Armenian government, implemented projects totaling $550 million between 2007 and 2017. In 2008 they co-founded the National Competitiveness Foundation of Armenia, a public-private partnership, and Afeyan met with Prime Minister Tigran Sargsyan in 2009 and 2012 as a member of its board. Vardanyan founded UWC Dilijan, an international school in the Armenian mountains, in 2014; Afeyan sits on its board.
The third partner was Vartan Gregorian, an Armenian born in Tabriz, Iran, who became president of the New York Public Library, then of Brown University, then of the Carnegie Corporation of New York — an immigrant who spent his life running America's temples of learning. Introducing Gregorian at a 2019 tribute in Boston, Afeyan said, "There is really no word to describe what he is. He serves as a role model and mentor to me. I look up to him even though he is half my size." The room laughed. It was the kind of joke you make about someone you revere.
In 2015, on the hundredth anniversary of the genocide, the three men co-founded the Aurora Humanitarian Initiative. It included 100 LIVES, a project to locate and preserve the stories of survivors and rescuers, and, beginning in 2016, the Aurora Prize for Awakening Humanity — awarded annually to an individual who has faced personal risk to enable others to survive, with $100,000 for the winner and $1 million directed to organizations the laureate chooses. The design is a quiet act of genealogy. The prize does not honor victims. It honors rescuers — people who, at risk to themselves, pulled others out of the path of destruction. Its founders' families exist because people like that once existed.
The rescue impulse turned political when the history began repeating. During the 2020 Nagorno-Karabakh war, Afeyan wrote to the New York Times under the headline "Armenians Under Fire: Who Will Help?" "When world powers step in to stop unfolding atrocities," he wrote, "it sends a signal to aggressors that annexing land or destroying a people and culture will not be tolerated." On April 24, 2024, as Armenians were again being killed and displaced, he took what he called "the extraordinary step" of placing a letter to the global community in the New York Times, the Washington Post, and the Times of London. "My aim is both to raise awareness, and raise the alarm."
By then the partnership had suffered its own catastrophe. Vardanyan had gone to Nagorno-Karabakh and served in its government; after Azerbaijan took the territory in 2023, he was detained, and the Armenian press would still be counting the years of his captivity in September 2026. In a November 2023 interview with the Armenian outlet Aravot, Afeyan defended his partner in a single rhetorical question: "Just ask yourself who is more renowned than Ruben?" Of the three men who founded Aurora to honor those who risked themselves for others, one has died — Gregorian, in 2021 — and one is a prisoner. The third keeps running the machine. The Aurora Humanitarian Initiative is now led by his daughter, Armine.
In 2016, before all that, Afeyan and Vardanyan had joined Charles Aznavour and others in signing an open letter, timed to the 110th anniversary of the Armenian General Benevolent Union and printed in the New York Times. "Delaying action and investment will mean that a vulnerable state remains at risk," Afeyan said then, "and the alternative, remaining unengaged, is indefensible." Aznavour, the singer who was born in Paris to Armenian refugees and became France's Sinatra, contributed the bleaker sentence: "Many great civilizations in the history of humanity have disappeared into oblivion." The two men were saying the same thing in different keys. One was an engineer. The other had spent seventy years singing in a language that was not his parents'.
One Hundred Percent, Three Times
Noubar Afeyan became a citizen of the United States in 2008. That same year, he received the Ellis Island Medal of Honor — an award granted, in its own description, to outstanding Americans "who have distinguished themselves as United States citizens." The timing is deliciously off. He had lived and worked in the country for a quarter century, taken a company public, helped birth Celera, built a venture firm, and he was honored for distinguished citizenship in roughly the same breath as he acquired it. The immigrant's calendar is always a little out of sync with the official one.
The honors kept coming, and almost all of them were immigrant honors. The Carnegie Corporation named him a Great Immigrant in 2016, quoting him from Forbes: "What keeps you from innovating is being comfortable. If you're an immigrant, then you're used to being out of your comfort zone." The International Institute of New England gave him its Golden Door Award in 2017. MIT invited him onto its governing Corporation. The Boston Symphony Orchestra put him on its board — a natural destination for the son of a woman who studied piano at the Paris Conservatory.
When the first Trump administration imposed its travel ban in January 2017, Afeyan was among the first prominent biotech figures to object in public, and his objection was characteristically engineered: an argument from industrial history rather than sentiment. The ban, he said, "is regressive along the very dimensions that enabled the US to be the founders and leaders of the biotechnology industry — innovation, entrepreneurship, opportunity and fairness." He added a detail only someone steeped in the diaspora would think to reach for: Steve Jobs, the biological son of a Syrian immigrant, had been raised by an adoptive mother, Clara, who was ethnically Armenian, the child of parents who had escaped Ottoman Turkey.
On September 18, 2019, about five hundred people gathered at the InterContinental Hotel in Boston for a tribute to Afeyan that doubled as a fundraiser for the city's Armenian Heritage Park, on the Rose Kennedy Greenway near Faneuil Hall, where new citizens are sworn in. The evening raised $700,000. Afeyan used his remarks to offer an inventory of the immigrant experience: "hope, optimism, fear, uncertainty, struggle, leaving, adaptation, courage and above all, the feeling of being uprooted and being rootless." Then the turn: "What is good about immigrants is that they are the ultimate founders; they are the founders of a new life."
He spoke about his children, who descend from an Armenian father and a Swedish mother. "They are 100 percent Armenian, 100 percent Swedish and 100 percent American," he said. The arithmetic is impossible, which is the point. Three hundred percent is the kind of total you get when identity refuses to be a zero-sum allocation — a refusal that a man who grew up stateless in Lebanon, Canadian in Quebec, and newly American in his mid-forties might feel more acutely than most. Two of the children went to MIT; at the 2024 commencement he named Taleen and Lena from the stage.
In 2022, he flew to Laval, Quebec, for the groundbreaking of a Moderna vaccine plant, alongside Prime Minister Justin Trudeau and Moderna president Stephen Hoge. It had been forty-seven years since the family had landed in Montreal. "Our destination was Montréal, Canada," he wrote that day, "a place where my father felt confident he could start over and rebuild a business." The boy who arrived "speaking imperfect French, having never experienced snow, ridden a city bus, or set foot in a biology or chemistry lab, could not have imagined that he would later return to this city and be part of a still-unfolding chapter in new and novel medicines." He signed off: "Thank you, Canada. It's nice to be back."
The stories he tells about himself have increasingly become a genre; in 2025 he sat for the MIT New Colossus Project, a series of conversations with first-generation immigrants in the United States, named, of course, for Emma Lazarus's sonnet at the base of the Statue of Liberty. In it and elsewhere he returns to the formulation he gave the Kuo Sharper Center: "I've come to view innovation as intellectual immigration. If you are a physical immigrant, or you've been displaced or dislocated, then you can use that gift … to channel yourself into actually doing things that other people around you won't do."
That summer, he and Anna signed the Giving Pledge. In January 2025, the White House awarded him the National Medal of Technology and Innovation. His net worth, which Forbes had placed at $3.3 billion in November 2021 at the height of the Moderna boom, had drifted to $1.9 billion by the fall of 2025, as the company that made him a billionaire slid from global savior to political target. He did not seem to talk about the number much. He was busy, as ever, with numbers of a different kind — LS-something, the next project that would either die anonymously or earn a name.
The Train at Belemedik
Which brings us back to the bedroom, and to Armenouhi's brothers.
In 1914, Bedros and Nerses were taken from Adapazar, a town near Istanbul, to be killed. They got out, Afeyan says, "by bribing people or promising people they'd pay them money if they helped them escape," and made their way back to Istanbul, where the family lived. In 1915 they were spotted, recaptured, and put on a train headed for a town on the border with Syria, from which they were to be marched into the desert to die.
The train stopped at a railway town called Belemedik. It was a staging post on the line the Germans were building from Berlin to Baghdad, and the Germans needed skilled workers. Bedros and Nerses were highly educated. They spoke fluent German. They had blue eyes. On the strength of those things — the language, the training, the color of their irises — they were taken off the train and hired, one as a bookkeeper and one as a supply manager. Competence as a survival credential, again. Usefulness to the people with power, again. Selection, by the most arbitrary and terrible criteria, again.
And then they did something with it. As the deportation trains passed through Belemedik, the two brothers would board them. They walked the cars looking for people they could help escape — and not just anyone. "Clerics, educators, writers, doctors," Afeyan says: the people who could, in the family's phrase, resurrect the Armenian nation. They were choosing, from among the condemned, the ones who might rebuild what was being destroyed. A bookkeeper and a supply manager running the most desperate portfolio-selection process imaginable, under a deadline measured in minutes, against odds no venture capitalist will ever face.
It did not make them feel like heroes. "Armenouhi used to say they felt terrible," Afeyan recalls, "knowing the other people left on the train were surely going to go die."
She told him that, in Beirut, in the bedroom with the window that looked out over the red-tiled roofs of Roman, Ottoman, and Byzantine buildings and beyond to the Mediterranean — an old woman in one bed and a boy in the other, and between them a train stopped at a station in the Taurus Mountains, two young men walking its length, the doors still open.
Part IIThe Playbook
What follows is an attempt to extract, from four decades of Afeyan's work, the operating principles that seem to explain it. Some are explicit — he has said them, repeatedly, in lectures and letters. Others are inferred from the pattern of his decisions. All of them sit on an unusual foundation: the conviction that innovation, which nearly everyone treats as a matter of genius or luck, can be engineered the way a chemical process can be engineered, with inputs, selection, and yield. The principles are not a recipe for being Noubar Afeyan. They are a set of tools for anyone trying to work, as he puts it, beyond the adjacencies.
The principles
- 1.Treat displacement as training.
- 2.Work future-back, not present-forward.
- 3.Use unreasonableness as a filter.
- 4.Number before you name.
- 5.Run evolution on purpose.
- 6.Entrepreneur in parallel, not in series.
- 7.Bet on the platform, not the product.
- 8.Build tools for the new breed.
- 9.Recruit skeptics with stakes, not arguments.
- 10.Practice paranoid optimism.
- 11.Design your ecosystem to bicycle range.
- 12.Defend the conditions of your own success.
Principle 1
Treat displacement as training
Afeyan's most repeated idea is that innovation is "intellectual immigration." The physical immigrant, he argues, has already done the hardest thing an innovator must do: leave a place where the rules are known for a place where they aren't, and rebuild competence from zero. He describes the immigrant experience as a list — "hope, optimism, fear, uncertainty, struggle, leaving, adaptation, courage" — that reads, not coincidentally, like a description of the first two years of a startup.
The usable insight is not "be an immigrant." It is that the discomfort of dislocation is a skill, and that skills atrophy without practice. "What keeps you from innovating is being comfortable," he told Forbes. Flagship institutionalizes the dislocation: its teams are asked to throw themselves "off balance" deliberately, to leave the comfort of known domains for "the distant white spaces where accepted wisdom doesn't apply." A firm full of people who have never been forced to restart can still choose to restart on purpose.
For individuals, the implication is uncomfortable. Expertise is a kind of citizenship — a set of rights and assumptions in a domain you know. The breakthroughs live just outside the border.
Tactic: Once a year, deliberately move yourself or a team into a domain where your existing expertise confers no status, and measure what you learn in the first ninety days.
Principle 2
Work future-back, not present-forward
Afeyan distinguishes between two kinds of innovation. Continuous, adjacency-oriented innovation should be "thought of as from the present going forward" — incremental improvement on what already exists, the kind of work that experts, funders, and incumbents can easily evaluate because, as he puts it, "you could pretty much see it." Breakthrough innovation runs the other direction: "something that you really want to think from the future back to the present," envisioning a future state "without necessarily knowing how we get there from here."
The trap, in his telling, is structural. The three great funders of innovation — the NIH, corporate R&D, and venture capital — all assess value by asking experts whether something is likely to work. Experts can only evaluate what's proximal. So capital systematically flows toward adjacency, and discontinuous ideas starve. Moderna's founding question — "What if you could use the human body to make any drug that you want?" — could not have been justified present-forward. It could only have been reasoned backward from an imagined endpoint.
He is careful not to overcorrect. Companies need both directions, he argues, attacking the space "from both directions." But the future-back motion has to be organized as deliberately as the present-forward one, or it will never happen at all — because every existing incentive pushes the other way.
Tactic: For every strategic plan built from current capabilities forward, write a second plan that starts from an imagined end state ten years out and reasons backward to what must be true today.
Principle 3
Use unreasonableness as a filter
"Why do we expect extraordinary outcomes from reasonable people doing reasonable things?" Afeyan asked a room of entrepreneurs at MIT. "If all you're doing is being reasonable, you should expect a lot of competition, because that's what everybody else is doing."
This is more than a provocation. He uses unreasonable in what he calls "the literal sense of the word": an idea is unreasonable if it cannot be reasoned toward from what is currently known. That makes unreasonableness a measurable property rather than a vibe — and a useful screen. If an idea can be justified by today's evidence, someone else is likely already pursuing it. If it can't, it is either wrong or uncrowded. Flagship's job is to find the small subset of unreasonable ideas that turn out to be realizable, which he summarizes as "start with science fiction and take the fiction out."
The discipline is in the second half of that sentence. Flagship is not a home for dreamers who stop at the dream; it subjects every unreasonable proposition to brutal testing. But it refuses to let reasonableness be the entry criterion. "Every disruptive company," he told WBUR, "is trying to defy the gravity of reasonableness. The thing that keeps ideas firmly planted into mediocrity is what we're fighting."
Tactic: When reviewing a slate of ideas, flag the ones every expert in the room agrees are sensible — and ask whether that consensus is a reason to deprioritize them.
Principle 4
Number before you name
Flagship numbers its companies at birth — "We bless them with the indignity of having a number. That way, we can kill them" — and only the survivors earn names. Moderna was LS18 before it was Moderna.
The mechanism addresses the most expensive failure mode in innovation: emotional attachment to an idea that should die. A name creates identity, and identity creates defenders. A number creates nothing but a slot in a sequence. By denying projects a name until they have survived Flagship's "killer questions," the firm keeps the cost of killing low, which makes the rate of honest killing high, which is what makes the overall portfolio work.
There is a deeper inversion here. Most organizations reward the creation of projects and punish their cancellation. Afeyan built a system in which death is the expected outcome and survival must be earned — a culture that a 2021 STAT story summarized as having "a tolerance for failure but not for weakness."
F
The Flagship Life Cycle
How an idea moves from question to company, and where most die.
| Stage | What happens | Status |
|---|---|---|
| Exploration | In-house teams pose "what if?" questions in uncrowded scientific territory. | Explore |
| Numbered project | Promising questions receive a number (e.g., LS18), not a name, and face "killer questions." | Test |
| Termination | Most numbered projects die anonymously; the low emotional cost keeps the kill rate honest. | Kill |
| Named subsidiary | Survivors earn a name and operate as wholly owned Flagship subsidiaries. | Test |
| Outside capital and IPO | The strongest take outside investors and, ideally, go public; about 30 have done so. | Scale |
Tactic: Give every new initiative a code number and refuse to brand it until it has survived a defined set of kill criteria.
Principle 5
Run evolution on purpose
Afeyan describes Flagship's process as laboratory-based evolution: "variation is created systematically and selection pressure is applied iteratively to converge breakthrough ideas." His HBR article with Gary Pisano carries the thesis in its title: "What Evolution Can Teach Us About Innovation."
The analogy is not decorative. Evolution produces astonishing novelty without foresight, through two disciplines: generating lots of variation, and ruthlessly selecting among it. Most organizations do neither well. They generate too little variation (because ideas must be justified in advance) and apply too little selection (because killing projects is politically expensive). Flagship deliberately inflates both. The firm's insistence that "there was no 'aha' moment" behind Moderna is the evolutionary view stated plainly: the breakthrough was an accumulation of small, selected steps — chemical modifications, delivery systems, design software, manufacturing processes — not a flash of insight.
There is a shadow side to the metaphor, which Afeyan himself acknowledges in a different context: cancer, he says, "is a pure disease of evolution." Selection does not care about what it selects against. The innovator borrowing evolution's method has to supply the values that evolution lacks.
Tactic: Separate the generation of options from their evaluation — run a phase where no idea can be rejected, followed by a phase where every idea must survive explicit, pre-agreed tests.
Principle 6
Entrepreneur in parallel, not in series
The idea that launched Flagship came out of PerSeptive. While running one public company, Afeyan started spinning out and co-founding others, and noticed that doing several at once changed the learning. "The learning cycles of doing things at the same time is completely different," he told No Priors, because parallelism forces you "to think about the essence of what you're doing and what's reproducible, what has to be different in each case."
His logic is an argument by analogy to every other profession. Investors, lawyers, and consultants all operate in parallel. "If it was the case that you could only do one of these at a time, you would have serial venture capitalists." Only entrepreneurs are expected to be serial — one company, then another — which Afeyan reads as evidence that entrepreneurship has been treated as an art or a game rather than a profession. "Why isn't entrepreneurship a profession?" was his early-1990s refrain. Flagship is the answer: an institution where founding companies is the job, done repeatedly, with shared infrastructure, shared patents, shared business development, and shared memory.
P
Improvisational vs. Professional Entrepreneurship
Afeyan's critique of the founder myth, side by side with the Flagship model.
| Conventional wisdom | Afeyan's approach |
|---|---|
| The entrepreneur is someone — a heroic individual founder. | "Entrepreneuring" is something you do: "doing something, not being someone." |
| Founders start companies one at a time, in series. | Companies are created in parallel, sharing infrastructure and lessons. |
| Venture capital waits for pitches. | Almost 90 of ~110 Flagship companies were conceived in house. |
| Find product-market fit first. | Shape the solution and the need together, future-back. |
| Innovation is a bazaar where pharma goes shopping. | Build an "innovation supply chain" with professional rigor. |
| Success is idiosyncratic and lucky. | Breakthroughs can be produced by a repeatable process. |
Tactic: If you are building more than one thing, write down which parts of the process are identical across projects and centralize them, so each new effort starts on a platform rather than from scratch.
Principle 7
Bet on the platform, not the product
By 2018, Afeyan was describing a shift that Moderna would soon make famous: "people are making this less of a bet on a single drug, and more of a bet on a platform which can produce many drugs." He described Moderna not as one company but as "an assemblage of five or 10 different companies," with roughly ten times as many drugs in the clinic as most biotechs at a comparable stage.
The platform logic explains both Moderna's agony and its triumph. It meant spending over $2 billion and nearly a decade without an approved product — a profile that kept the company "non-consensus" even after its record IPO. It also meant that when SARS-CoV-2 arrived, the machinery to design, fabricate, test, and scale an mRNA vaccine already existed. The platform was the asset; the vaccine was, in a sense, its first demonstration.
M
From LS18 to a Billion Doses
A decade of platform-building compressed into one public proof.
2010
Building on modified-mRNA findings from Penn and Harvard labs, Flagship launches LS18, its 18th life-sciences platform project.
2011
Stéphane Bancel, then CEO of BioMérieux, initially calls the idea crazy, then joins Flagship and becomes CEO.
2015
Moderna reportedly valued at $3.5 billion with no approved product.
2018
IPO raises roughly $604 million, then the largest in biotech history.
2020
mRNA-1273 becomes the first SARS-CoV-2 vaccine to enter human trials; on November 15, Phase 3 results show it is highly effective.
2022
Moderna produces more than a billion COVID-19 doses per year at its peak.
The lesson travels beyond biotech. A product answers one question. A platform answers a category of questions, including ones nobody has asked yet. It costs more and takes longer, and it is the only thing that can respond when the world suddenly asks the question you didn't know you were preparing for.
Tactic: Before funding a product, ask what underlying capability it would require you to build — and whether that capability could generate ten more products if you built it properly.
Principle 8
Build tools for the new breed
Afeyan's first company did not come from a breakthrough in biology. It came from an analogy. David Packard told him that he and Bill Hewlett, trained in a then-new discipline, had built instruments for electrical engineers. Afeyan realized he was "becoming a new breed of engineer" in another new discipline. "Maybe I can create a company to make the instruments this field is going to need."
The principle is that new fields produce practitioners before they produce infrastructure, and that the infrastructure gap is one of the most reliable openings in business. PerSeptive did not have to bet on which drug would work; it sold the equipment everyone needed regardless. That position — supplying the frontier rather than gambling on a single outcome at the frontier — gave Afeyan a decade of revenue, a public company, and an unusually broad view of where the field was going. It is a recurring move in his career: Celera, too, was in some sense infrastructure, a company built to produce the data on which everything else would depend.
Tactic: Identify the newest credentialed discipline adjacent to your work and list the tools its practitioners are currently improvising — each improvisation is a product waiting to be built.
Principle 9
Recruit skeptics with stakes, not arguments
Stéphane Bancel's first reaction to Moderna — "You're crazy, it's never going to work" — is the reaction any rational executive should have had to an unreasonable idea. What changed his mind, by his own account, was that Afeyan didn't try "to force the issue in my brain." He made Bancel see "that it could change the world and that it was worth the risk."
This is a subtle and important technique. You cannot argue someone into believing an unreasonable proposition, because by definition the evidence is not yet there. Arguments invite counterarguments, and the skeptic usually wins on the current facts. What you can do is shift the question from "is this likely?" to "is this worth it?" — from probability to magnitude. The skeptic gets to keep their doubts. They simply decide that the size of the prize justifies acting under uncertainty. Afeyan's question to the world — "Why wouldn't you think you can actually change the world in the particular area you are working on?" — is the same move, made at scale.
Tactic: When recruiting someone to an improbable project, concede the odds openly and spend your time making the size of the outcome concrete.
Principle 10
Practice paranoid optimism
"I can see the scary part of just about everything, because we have to imagine it to try and go after it." Afeyan calls the posture paranoid optimism, and he locates its origin in the immigrant experience: the expectation that things can go catastrophically wrong, held alongside the conviction that they can be rebuilt.
The two halves discipline each other. Optimism without paranoia produces the fantasies that venture culture is famous for. Paranoia without optimism produces paralysis. Together they produce a specific behavior: imagining failure in detail in order to work against it. Flagship's "killer questions" are institutionalized paranoia. Its insistence on pursuing "transformative if true" ideas is institutionalized optimism. His 2024 annual letter performs the same trick at a civilizational level, naming the "polycrisis" and then, in the next breath, coining "poly-opportunity."
Paranoia also proved predictive. Years before the 2025 attacks on mRNA, he was warning that politicizing science would not "stop at mRNA." The paranoid optimist sees the storm early — and declines, when it arrives, to simply hang on to the nearest tree.
Tactic: For every major bet, write a specific pre-mortem describing exactly how it fails, then write the countermeasure for each failure mode before committing capital.
Principle 11
Design your ecosystem to bicycle range
"Everything we do is a bicycle ride away from here," Afeyan says of Flagship's Cambridge base. He is explicit that an ecosystem is not a cluster of service providers. It is, as he wrote in his 2024 letter, a set of "mutually reinforcing" relationships among academic science, hospitals, patients, capital, and talent, in which "our interactions elevate us to more than merely the sum of our parts."
The twist in his thinking is the phrase "ecosystems of our own design." Most people treat ecosystems as weather — you either live somewhere with a good one or you don't. Afeyan treats them as engineered systems. Flagship itself is a designed micro-ecosystem: about six hundred people, more than half of them scientists, shared functions in finance, regulatory, business development, and AI, a pipeline of Fellows who learn the process each summer, and alumni CEOs like Bancel who become "the beneficiary of the same thing that preceded him." His Armenian work — IDeA, UWC Dilijan, FAST, the National Competitiveness Foundation — is an attempt to design an ecosystem for an entire country.
Tactic: Map every person and institution your work depends on, then deliberately close the physical and organizational distance to the five that matter most.
Principle 12
Defend the conditions of your own success
Afeyan's public interventions — against the 2017 travel ban, for American intervention in the 2020 Nagorno-Karabakh war, against politicians and judges overruling regulators in 2023, against the "sledgehammer" taken to the "miracle machine" in 2026 — can look like a separate career from his business. They are not. Each defends a condition that made his work possible: humane immigration law, which let a refugee family land in Montreal; scientific authority, which lets a platform company bring a novel medicine to market; the survival of a people whose story he carries.
He frames the travel ban as "regressive along the very dimensions that enabled the US to be the founders and leaders of the biotechnology industry." The logic is precise. Institutions that produce breakthroughs are not self-sustaining. They rest on laws, norms, and public trust that can be eroded. A founder who benefits from those conditions and stays silent while they are dismantled is, in a sense, liquidating the platform.
The cost is real. Afeyan has watched his signature company become a political target, his net worth fall, and one of his closest partners imprisoned. He has kept speaking anyway — which may be the most immigrant thing about him, the knowledge that "remaining unengaged," as he put it in 2016, "is indefensible."
Tactic: Identify the two or three public conditions — legal, regulatory, cultural — without which your work would be impossible, and commit time each year to defending them in public.
Free playbook
Get The Business Model Playbook
58 business models, one visual page each: how the money flows, the metrics that matter, and who runs it. Free when you join the Faster Than Normal email.
Free. No spam. Unsubscribe anytime.
Part IIIQuotes and Maxims
In their words
— Noubar Afeyan, to Forbes (2016)It's a complete misnomer. Do you know what the root of that word is? It's the French word for undertaker. It's the state of being something. I think it should be 'ing.' Entrepreneuring.
— Noubar Afeyan, to Semafor (November 2025)We number all of our companies at birth. We bless them with the indignity of having a number. That way, we can kill them. And the ones that don't die end up with a name.
— Noubar Afeyan, to WBUR (2018)We're using science that has not yet been discovered, in order to come up with treatments that have not yet been described, for diseases that are not well understood.
— Noubar Afeyan, on his great-aunt Armenouhi, Aurora Humanitarian InitiativeI remember her saying that the best way to win is to create, to excel, to do great things. By 'win' she meant beat the Genocide.
— Noubar Afeyan, at a 2019 tribute in BostonWhat is good about immigrants is that they are the ultimate founders; they are the founders of a new life.
Maxims
- Discomfort is a credential. The experience of restarting from zero is the same skill that breakthrough work demands; practice it before you are forced to.
- Reason backward from the future. Adjacent ideas can be justified by today's evidence; breakthroughs can only be reached from an imagined endpoint.
- Unreasonable is a measurement, not an insult. If every expert agrees an idea is sensible, assume you have company.
- Name only what survives. A number can be killed cleanly; a brand acquires defenders.
- Generate widely, select ruthlessly. Novelty comes from variation plus selection, and most organizations starve both.
- Entrepreneuring is a verb. Treat company creation as a professional practice done in parallel, not a heroic identity performed once.
- Build the platform before the product. A capability that answers a category of questions will be ready when the world asks one you didn't anticipate.
- Supply the new breed. Every new discipline needs tools before it knows it does.
- Persuade with magnitude, not probability. Concede the odds; make the prize vivid.
- Defend the soil you grew in. The laws, norms, and trust that made your success possible will not defend themselves.
